Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL593 in Frontotemporal Dementia
NCT05262023Phase 2Active, not recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of DNL593 in frontotemporal dementia (FTD) (4 arms), sponsored by Denali Therapeutics Inc. Primary endpoints: Treatment-Emergent Adverse Events at 18 months, Clinically Significant Abnormalities in Safety Laboratory Values at 18 months and 7 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
DNL593
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT05262023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262023.